Latest news with #AdaptiveBiotechnologies
Yahoo
3 days ago
- Business
- Yahoo
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the 'Investors' section of the company website at: The webcast will be archived and available for replay within 24 hours after the event. About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@
Yahoo
11-06-2025
- Business
- Yahoo
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adaptive Biotechnologies (ADPT) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Adaptive Biotechnologies is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the latest available data, ADPT has gained about 74.5% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Adaptive Biotechnologies is outperforming its peers so far this year. Another stock in the Medical sector, CVS Health (CVS), has outperformed the sector so far this year. The stock's year-to-date return is 43.2%. In CVS Health's case, the consensus EPS estimate for the current year increased 4.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 0.2% so far this year, meaning that ADPT is performing better in terms of year-to-date returns. CVS Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #69. The industry has moved -0.9% so far this year. Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and CVS Health. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adaptive Biotechnologies Corporation (ADPT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
03-06-2025
- Business
- Business Wire
Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors
WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (Nasdaq: Z) and Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. 'We are pleased to welcome Chad to Grindr's Board of Directors,' said Grindr CEO George Arison. 'His broad experience and deep expertise in helping grow successful public companies will be an invaluable asset to Grindr's Board.' A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Officer and Chief Operating Officer for Capella Space, a satellite-based earth observation company; as well as the Chief Financial Officer at Adaptive Biotechnologies, an immune-driven medicine company; and Zillow Group, a leading real-estate marketplace company. During his tenure, Cohen played a pivotal role in leading both Zillow and Adaptive Biotechnologies through their IPOs and scaling both companies through periods of hypergrowth. Additionally, Cohen served as a Board Director and Chair of the audit committee for Vacasa, Inc. (Nasdaq: VCSA), a vacation rental management platform, and for Trupanion, Inc. (Nasdaq: TRUP), a pet insurance company. Cohen was also an Operating Partner at Cota Capital, Assistant Controller at Ticketmaster Entertainment, VP and Assistant Controller at Countrywide Bank, and Supervising Senior Auditor at Ernst & Young. He began his career as a Financial Planning Analyst at Novellus Systems. Today, Cohen serves as Founding Partner and CEO at Scala Advisors, LLC, where he leverages his expertise to advise public and private companies on finance, business operations, and investor relations initiatives. With Cohen's appointment, Director Gary Horowitz stepped down from Grindr's Board. 'We are pleased to welcome Chad to Grindr's Board of Directors,' said Grindr CEO George Arison. 'His broad experience and deep expertise in helping grow successful public companies will be an invaluable asset to Grindr's Board. I look forward to collaborating with Chad as we continue to expand Grindr's capabilities as the Global Gayborhood in Your Pocket. I also want to thank both Gary Horowitz for his dedicated service to Grindr and Nathan Richardson for serving as our Audit Committee Chair during our first three years as a public company, and I'm happy that Nathan is continuing on the Board and the Audit Committee.' 'Grindr has established itself as the premier social platform and market leader in dating apps for the gay community. Its outstanding business performance and strong financial profile is a testament to its leading market position, and I am thrilled to be joining the Board of Directors,' said Cohen. 'I look forward to providing my expertise and support to George and the management team to advance Grindr's mission.' About Grindr With more than 14.5 million average monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket™, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015, Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.
Yahoo
28-05-2025
- Business
- Yahoo
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Adaptive Biotechnologies' management is scheduled to participate in a fireside chat on Wednesday, June 11th at 5:40 a.m. Pacific Time / 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the 'Investors' section of the company website at: About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57
A week ago, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed expectations at US$52m, beating expectations by 24%. Adaptive Biotechnologies reported a statutory loss of US$0.20 per share, which - although not amazing - was much smaller than the analysts predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Our free stock report includes 3 warning signs investors should be aware of before investing in Adaptive Biotechnologies. Read for free now. Taking into account the latest results, the consensus forecast from Adaptive Biotechnologies' eight analysts is for revenues of US$216.0m in 2025. This reflects a meaningful 14% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 11% from last year to US$0.83. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$212.7m and losses of US$0.92 per share in 2025. Although the revenue estimates have not really changed Adaptive Biotechnologies'future looks a little different to the past, with a favorable reduction in the loss per share forecasts in particular. View our latest analysis for Adaptive Biotechnologies The average price target rose 8.8% to US$10.57, with the analysts signalling that the forecast reduction in losses would be a positive for the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Adaptive Biotechnologies, with the most bullish analyst valuing it at US$13.00 and the most bearish at US$7.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Adaptive Biotechnologies' growth to accelerate, with the forecast 19% annualised growth to the end of 2025 ranking favourably alongside historical growth of 13% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Adaptive Biotechnologies is expected to grow much faster than its industry. The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Adaptive Biotechnologies going out to 2027, and you can see them free on our platform here.. Even so, be aware that Adaptive Biotechnologies is showing 3 warning signs in our investment analysis , you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
